Literature DB >> 28989465

A whole health economy approach to reducing MRSA bacteraemia incidence in diabetic foot ulcer patients.

Fiona Branton1, Elaine Cathcart2, Elaine Bellamy3.   

Abstract

INTRODUCTION: Ulceration of the foot is a common problem among diabetic patients. Infection is a major risk in diabetic foot ulcers (DFU) and many of these are caused by Staphylococcus aureus, in particular meticillin-resistant strains (MRSA). The control and management of MRSA remains a significant challenge and all healthcare organisations in England are required to meet Zero Tolerance Objectives for cases of MRSA bacteraemia (MRSAB). This paper describes a collaborative approach across the health economy to investigate factors contributing to the acquisition of MRSA and MRSAB among DFU patients and make improvements to care to reduce the risk of healthcare-associated infections.
METHODS: A collaborative approach between acute and community healthcare providers and commissioners was used to conduct Root Cause Analysis and drive improvement to prevent MRSA transmission in DFU patients.
RESULTS: Screening of all DFU patients was initiated after 6 MRSAB were found to be associated with in DFU. In total 15 patients with the same MRSA antibiogram were identified. Following the implementation of actions focused on isolation, wound management, screening and cleaning no further cases were identified.
CONCLUSION: This outbreak has demonstrated the value of cross-sector collaboration in investigating HCAI in patients with DFU, improving patient care and reducing the risk of MRSA transmission in these vulnerable patents.

Entities:  

Keywords:  Patient experience; antimicrobial drug resistance; bacteraemia; diabetic foot ulcer; meticillin-resistance Staphylococcus aureus (MRSA); outbreak

Year:  2016        PMID: 28989465      PMCID: PMC5074211          DOI: 10.1177/1757177416633514

Source DB:  PubMed          Journal:  J Infect Prev        ISSN: 1757-1782


  13 in total

1.  Concordance is not synonymous with compliance or adherence.

Authors:  J Simon Bell; Marja S Airaksinen; Alan Lyles; Timothy F Chen; Parisa Aslani
Journal:  Br J Clin Pharmacol       Date:  2007-09-13       Impact factor: 4.335

2.  Psychological impact of short-term isolation measures in hospitalised patients.

Authors:  M W M Wassenberg; D Severs; M J M Bonten
Journal:  J Hosp Infect       Date:  2010-04-10       Impact factor: 3.926

3.  Communitarianism and the ethics of communicable disease: some preliminary thoughts.

Authors:  Cara M Cheyette
Journal:  J Law Med Ethics       Date:  2011       Impact factor: 1.718

4.  Patient experience of source isolation: lessons for clinical practice.

Authors:  Ruth Linda Barratt; Ramon Shaban; Wendy Moyle
Journal:  Contemp Nurse       Date:  2011-10       Impact factor: 1.787

5.  Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem.

Authors:  C N Dang; Y D M Prasad; A J M Boulton; E B Jude
Journal:  Diabet Med       Date:  2003-02       Impact factor: 4.359

6.  MRSA colonization and the risk of MRSA bacteraemia in hospitalized patients with chronic ulcers.

Authors:  M C Roghmann; A Siddiqui; K Plaisance; H Standiford
Journal:  J Hosp Infect       Date:  2001-02       Impact factor: 3.926

Review 7.  Diagnosing and treating diabetic foot infections.

Authors:  Benjamin A Lipsky; Anthony R Berendt; John Embil; Fausto De Lalla
Journal:  Diabetes Metab Res Rev       Date:  2004 May-Jun       Impact factor: 4.876

Review 8.  The burden of diabetic foot ulcers.

Authors:  G E Reiber; B A Lipsky; G W Gibbons
Journal:  Am J Surg       Date:  1998-08       Impact factor: 2.565

9.  An exploration of the psychologic impact of contact isolation on patients in Singapore.

Authors:  Margaret Mei Ling Soon; Elizabeth Madigan; Katherine R Jones; Robert A Salata
Journal:  Am J Infect Control       Date:  2013-05-08       Impact factor: 2.918

Review 10.  Adverse effects of isolation in hospitalised patients: a systematic review.

Authors:  C Abad; A Fearday; N Safdar
Journal:  J Hosp Infect       Date:  2010-10       Impact factor: 3.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.